skip to Main Content

Submitted Case

2022
1. Submitted Case
2. Submitted Case
3. Submitted Case
4. Peer Review
5. Submitted Case
6. Submitted Case
7. Submitted Case
8. Submitted Case
9. Peer Review
10. Submitted Case
11. Submitted Case
12. Submitted Case
13. Submitted Case
14. Submitted Case
15. Submitted Case
16. Submitted Case
17. Submitted Case
18. Submitted Case
19. Submitted Case
20. Submitted Case
21. Submitted Case
22. Submitted Case
23. Submitted Case
24. Submitted Case
25. Submitted Case
26. Submitted Case
27. Submitted Case
28. Submitted Case
Patient Information: (Do not provide name of the patient)
Age
  A general question: would it be appropriate to omit ADT when giving definitive RT for a high-risk prostate patient, who is high-risk only by virtue of extremely small-volume GG4 component (e.g. PSA 6.5 and Gleason 4+4 in 20% of 1/12 cores)?
Images
Session Name
  Dr. Ron Chen, Prostate Cancer, March 24, 2022
Session ID
  11401
created_by
  7717
post_id
  11401
Back To Top